{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.6","upperLimit":"96.2","value":"82"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Percentage of participants with lymphoma-related symptoms (B symptoms: fever, night sweats, or weight loss \\>10%) at baseline who achieved resolution of all B symptoms at any time during the treatment period.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"OG000","title":"Brentuximab Vedotin"}],"paramType":"NUMBER","populationDescription":"Participants with B symptoms at baseline","reportingStatus":"POSTED","timeFrame":"up to 12 months","title":"B Symptom Resolution","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percent of participants"}